Page last updated: 2024-08-21

alpha-aminopyridine and Cystadenocarcinoma, Serous

alpha-aminopyridine has been researched along with Cystadenocarcinoma, Serous in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Eismann, J; Gray, KP; Heng, YJ; Konstantinopoulos, PA; Matulonis, UA; Murphy, CJ; Nabavi, S; Vlachos, IS; Waldschmidt, JM; Wulf, GM	1

Other Studies

1 other study(ies) available for alpha-aminopyridine and Cystadenocarcinoma, Serous

Article	Year
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:2 Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cystadenocarcinoma, Serous; Female; Forkhead Transcription Factors; Gene Expression Profiling; Gene Fusion; Humans; Middle Aged; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines; Repressor Proteins; RNA-Seq; Triple Negative Breast Neoplasms	2020

Article

Year

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.

Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:2

Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cystadenocarcinoma, Serous; Female; Forkhead Transcription Factors; Gene Expression Profiling; Gene Fusion; Humans; Middle Aged; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines; Repressor Proteins; RNA-Seq; Triple Negative Breast Neoplasms

2020